Delpazolid

DRUG3 trials

Sponsors

LigaChem Biosciences, Inc.

Conditions

Infections and InfestationsMRSA BacteremiaMycobacterium Abscessus InfectionNontuberculous Mycobacterium InfectionPulmonary Tuberculosis

Phase 2

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

CompletedNCT04550832

LigaChem Biosciences, Inc.Infections and Infestations, Pulmonary Tuberculosis

Start: 2021-10-28End: 2023-09-11Updated: 2025-09-16

A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

TerminatedNCT05225558

LigaChem Biosciences, Inc.MRSA Bacteremia

Start: 2022-04-26End: 2024-03-18Updated: 2025-05-06

Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex

Active, not recruitingNCT06004037

LigaChem Biosciences, Inc.Mycobacterium Abscessus Infection, Nontuberculous Mycobacterium Infection

Start: 2024-01-16End: 2026-12-30Target: 20Updated: 2025-08-22

Related Papers

Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial.

2026-02-18

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.

2025-07-084 citations

Comparative pharmacokinetics study of two tablet formulations of delpazolid, a novel oxazolidinone class antibiotic.

2024-12-18

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.

2023-06-0611 citations